Amanda Toath
Medical · Boswell, PANPI 1083666465
Payments from drug & device makers
Across 195 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$467
- GSK$358
- Novo Nordisk$348
- Lilly USA, LLC$309
- Pfizer$298
- AbbVie$251
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,22199%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $467 |
| GSK | 22 | $358 |
| Novo Nordisk | 18 | $348 |
| Lilly USA, LLC | 20 | $309 |
| Pfizer | 20 | $298 |
| AbbVie | 17 | $251 |
| E.r. Squibb & Sons, L.L.C. | 8 | $154 |
| Amgen | 9 | $138 |
| Boehringer Ingelheim | 7 | $122 |
| Merck | 7 | $117 |
| Astellas Pharma US Inc | 5 | $104 |
| Abbott | 5 | $93 |
| Exact Sciences | 4 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $81 |
| Sanofi-aventis U.S. LLC | 5 | $64 |
| Bayer | 3 | $52 |
| Johnson & Johnson | 3 | $44 |
| UCB, Inc. | 1 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,267 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 191 | $233,390 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 216 | $205,859 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 180 | $173,332 |
| JardianceEmpagliflozin | 122 | $108,705 |
| TrulicityDulaglutide | 81 | $103,649 |
| EliquisApixaban | 74 | $85,802 |
| FarxigaDapagliflozin Propanediol | 68 | $65,793 |
| MyrbetriqMirabegron | 97 | $50,230 |
| Xigduo XrDapaglifloz Propaned/Metformin | 37 | $48,449 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $46,297 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $39,789 |
| RybelsusSemaglutide | 25 | $30,194 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $28,612 |
| XareltoRivaroxaban | 25 | $25,818 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $25,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Combivent Respimat, Tradjenta | $122 | $332,691370 claims |
| Novo NordiskOzempic, Rybelsus | $348 | $263,584216 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $358 | $189,396213 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $309 | $125,43695 claims |
| PfizerEliquis | $298 | $85,80274 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $467 | $82,96586 claims |
| Astellas Pharma US IncMyrbetriq | $104 | $50,23097 claims |
| MerckJanuvia, Janumet Xr | $117 | $44,00849 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $64 | $28,61229 claims |
| Johnson & JohnsonXarelto | $44 | $25,81825 claims |
| AbbVieLinzess | $251 | $25,24735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Boswell
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.